IA40 Spotlight: A-Alpha Bio's David Younger on machine learning in biotech, building cross-functional teams

This week on Founded & Funded, Partner Chris Picardo is talking with A-Alpha Bio Co-founder and CEO David Younger for our first Intelligent Application 40 Spotlight episode of 2023. We announced the 2022 IA40 winners in October, and A-Alpha was the first biotech company to make the list, which was no surprise to us. As one of our portfolio companies, we know the work David and his team are doing at the intersections of biological and data/computer sciences will change the world — but having a group of judges agree with us makes us all the more certain. Protein interactions govern just about all of biology and A-Alpha uses synthetic biology and machine learning to measure and engineer protein-protein interactions, speeding up a traditionally slow wet lab process. The company's proprietary platform — AlphaSeq — uses genetically engineered cells to experimentally measure millions of protein-protein interactions simultaneously, generating enormous amounts of data to inform the discovery and development of therapeutics. It is within that enormous amount of data that the company is adding to every day that so many answers will start to be found as the company is able to use machine learning to train predictive models and begin predicting new antibody sequences that could be effective against different viruses and diseases — improving the way that we are able to discover drugs. Chris and David dive into that future that A-Alpha is working toward and so much more — the power of data engineering, building business models around data, building cross-functional teams, having both tech and biotech-focused investors. It is an episode you won't want to miss.